Morgan Stanley Nuvectis Pharma, Inc. Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 24,693 shares of NVCT stock, worth $148,651. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,693
Previous 6,977
253.92%
Holding current value
$148,651
Previous $68,000
170.59%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding NVCT
# of Institutions
50Shares Held
3.2MCall Options Held
44.5KPut Options Held
50.1K-
Vanguard Group Inc Valley Forge, PA667KShares$4.01 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.39 Million5.37% of portfolio
-
Iridian Asset Management LLC373KShares$2.24 Million1.01% of portfolio
-
Baldwin Brothers LLC350KShares$2.11 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA285KShares$1.72 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $88.1M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...